EBV阳性弥漫大B细胞淋巴瘤非特指型的临床病理特征与生存分析
该回顾性研究纳入2006至2019年1696例DLBCL-NOS,其中EBV阳性70例(患病率4.1%)。中位年龄68.5岁,79%为III-IV期,48%有结外病变,14%合并HLH。5年PFS和OS分别为52.7%和54.8%。多因素分析显示年龄>50岁和HLH与更短PFS和OS相关。与EBV阴性对照相比,EBV阳性仅在>50岁患者中与更短OS相关。
要点
- EBV阳性DLBCL-NOS患病率4.1%,多呈非生发中心表型,CD30和PD-L1高表达。
- 年龄>50岁和HLH是PFS和OS的独立不良预后因素。
- EBV阳性仅在>50岁患者中与更短OS相关,年轻患者无显著差异。
核心结论
- EBV阳性DLBCL-NOS患病率4.1%,老年和HLH患者预后差,EBV阳性仅在>50岁患者中与更短OS相关。
研究设计与样本
- 回顾性研究,纳入2006至2019年1696例DLBCL-NOS,其中EBV阳性70例。
主要发现
- 中位年龄68.5岁,79%为III-IV期,48%有结外病变,14%合并HLH。
- 46例呈多形性模式,21例呈单形性模式,全部为非生发中心B细胞表型。
- 肿瘤细胞CD30表达98%,PD-L1表达95%;EBV潜伏型II型88%,III型12%。
- 中位随访48个月,5年PFS为52.7%,5年OS为54.8%。
- 多因素分析:年龄>50岁与更短PFS相关(HR 14.01,95%CI 2.34-83.97)和更短OS相关(HR 12.41,95%CI 1.65-93.53);HLH与更短PFS相关(HR 5.78,95%CI 2.35-14.23)和更短OS相关(HR 6.09,95%CI 2.42-15.30)。
临床怎么用
- 对EBV阳性DLBCL-NOS患者应评估年龄和HLH状态以进行预后分层。
- 老年EBV阳性患者可能需更密切监测和个体化治疗。
局限性
- 回顾性研究设计,样本量有限(70例EBV阳性),可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this retrospective study, we report 70 cases of Epstein-Barr virus (EBV)+ diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS) among 1696 DLBCL-NOS cases diagnosed between 2006 and 2019 (prevalence of 4.1%). At diagnosis, median age was 68.5 years; 79% of the cases presented with an advanced-stage disease (III-IV), 48% with extranodal lesions, and 14% with an hemophagocytic lymphohistiocytosis (HLH) (8 at diagnosis and 1 on therapy). A total of 46 cases presented a polymorphic pattern, and 21 were monomorphic. All had a non-germinal center B phenotype, with the majority of tumor cells expressing CD30 and programmed death ligand 1 (98% and 95%, respectively). Type II and III EBV latency was seen in 88% and 12% of the cases, respectively. Patients were treated with immunochemotherapy (59%) or chemotherapy (22%), and 19% received palliative care due to advanced age and altered performance status. After a median follow-up of 48 months, progression-free survival (PFS) and overall survival (OS) at 5 years were 52.7% and 54.8%, respectively. Older age (>50 years) and HLH were associated with shorter PFS and OS in multivariate analysis (PFS: hazard ratio [HR], 14.01; 95% confidence interval [CI], 2.34-83.97; and HR, 5.78; 95% CI, 2.35-14.23; OS: HR, 12.41; 95% CI, 1.65-93.53; and HR, 6.09; 95% CI, 2.42-15.30, respectively). Finally, using a control cohort of 425 EBV- DLBCL-NOS, EBV positivity was associated with a shorter OS outcome within patients >50 years (5-year OS, 53% [95% CI, 38.2-74] vs 60.8% [95% CI, 55.4-69.3], P = .038), but not in younger patients.
引用
- Bourbon E, Maucort-Boulch D, Fontaine J, et al. Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified. Blood Adv. 2021. PMID: 34427583. doi:10.1182/bloodadvances.2021004515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。